Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%
Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.
DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF. The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.
With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.
For more information email us @ firstname.lastname@example.org.
This entry was posted in Anti-coagulants, Atrial Fibrillation, Business Consultant, CVS Indications, DelveInsight's Drug Report, Pharma Consultant, Specialized Reports and tagged Business Consultant, Cardiovascular disease, collaborations, Competitive landscape, DelveInsight, Discovery, Drug, Hematological disorders, licensing opportunities, Market Forecasting, Market Research, market trends, Metabolic disorders, Phase III Pipeline, Pipeline, Pipeline coverage, Reports, SWOT ANALYSIS, technology assessments, Track your closest Competitors.